A Study To Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of ASP2408 After Multiple Dose Subcutaneous Injections in Patients With Rheumatoid Arthritis on Methotrexate

Exclusion Criteria

• •Subject has an ongoing infection or has had an infection requiring intravenous antibiotics within 1 month prior to Day 1.
• •Subject has a past history of serious opportunistic infection.
• •Subject has a positive Mantoux tuberculin skin or QuantiFERON-TB Gold test within 90 days of, or at Screening, and has not completed an adequate course of antimicrobial therapy per CDC guidelines.
• •Subject received any live or live-attenuated vaccine within 30 days prior to Day 1.
• •Subject received any of the following:
• •* Anakinra (Kineret®), etanercept (Enbrel®), or adalimumab (Humira®) within 60 days prior to Day 1.
• •* Rituximab (Rituxan®) or any other anti-CD20 antibody within 180 days prior to Day 1.
• •* Leflunomide (Arava®) within 60 days prior to drug dosing on Day 1, unless the subject has undergone cholestyramine washout at least 30 days prior to Day 1.
• •* Oral or injectable gold, azathioprine, penicillamine, cyclosporine, or tacrolimus within 30 days prior to Day 1.
• •* Cyclophosphamide within 180 days prior to Day 1.
• •Subject has received any CTLA4-Ig molecule (including, but not limited to abatacept \[Orencia®\] and belatacept \[Nulojix\]).
• •Subject has participated in a previous clinical study with treatment with ASP2408 or ASP2409 or has participated in another dose cohort of the current trial.
• •Subject has previously participated in any interventional clinical study, or has received an experimental agent within 56 days or 5 half-lives, whichever is longer, prior to Day 1.
• •Subject has a history of prolonged QT syndrome.